T. Rowe Price Associates
INBX icon

T. Rowe Price Associates’s Inhibrx INBX Stock Holding History

T. Rowe Price Associates’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$472K Buy
7,012
+1,678
+31% +$124K ﹤0.01% 2486
2025
Q4 		$422K Buy
+5,334
New +$363K ﹤0.01% 2472

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates's INBX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Inhibrx (INBX) stake by 31% in Q1 2026, buying an estimated $124K and bringing the position to 7,012 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #2486.

T. Rowe Price Associates first reported a position in INBX in Q4 2025 and has held it in 2 quarters since. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • T. Rowe Price Associates held 7,012 shares of Inhibrx worth $472K as of Q1 2026.
  • T. Rowe Price Associates bought 1,678 Inhibrx shares in Q1 2026, an estimated $124K.
  • Inhibrx made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2486 holding.
  • T. Rowe Price Associates first reported a position in Inhibrx in Q4 2025 and has held it in 2 quarters since.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.